Education
About Us
Working with TipRanks
Follow Us
Ocumension Therapeutics (HK:1477)
:1477
RESEARCH TOOLSreports
Total Valuation
Ocumension Therapeutics has a market cap or net worth of HK$7.46B. The enterprise value is HK$7.51B.
Market CapHK$7.46B
Enterprise ValueHK$7.51B
Share Statistics
Ocumension Therapeutics has 834,780,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding834,780,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Ocumension Therapeutics’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -8.04%.
Return on Equity (ROE)-0.07
Return on Assets (ROA)-0.07
Return on Invested Capital (ROIC)-8.04%
Return on Capital Employed (ROCE)-0.08
Revenue Per Employee853.39K
Profits Per Employee-546.54K
Employee Count489
Asset Turnover0.11
Inventory Turnover4.22
Valuation Ratios
The current PE Ratio of Ocumension Therapeutics is -10.84. Ocumension Therapeutics’s PEG ratio is -1.31.
PE Ratio-10.84
PS Ratio0.00
PB Ratio1.91
Price to Fair Value0.77
Price to FCF-61.94
Price to Operating Cash Flow-62.87
PEG Ratio-1.31
Income Statement
In the last 12 months, Ocumension Therapeutics had revenue of 417.31M and earned -268.27M in profits. Earnings per share was -0.39.
Revenue417.31M
Gross Profit225.06M
Operating Income-306.43M
Pretax Income-267.26M
Net Income-268.27M
EBITDA-260.05M
Earnings Per Share (EPS)-0.39
Cash Flow
In the last 12 months, operating cash flow was -114.38M and capital expenditures -18.14M, giving a free cash flow of -132.53M billion.
Operating Cash Flow-114.38M
Free Cash Flow-132.53M
Free Cash Flow per Share-0.16
Dividends & Yields
Ocumension Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.07
52-Week Price Change36.77%
50-Day Moving Average7.81
200-Day Moving Average5.65
Relative Strength Index (RSI)48.77
Average Volume (3m)10.37M
Important Dates
Ocumension Therapeutics upcoming earnings date is Aug 13, 2025, TBA (Confirmed).
Last Earnings DateMar 31, 2025
Next Earnings DateAug 13, 2025
Ex-Dividend Date―
Financial Position
Ocumension Therapeutics as a current ratio of 6.31, with Debt / Equity ratio of 0.68%
Current Ratio6.31
Quick Ratio6.02
Debt to Market Cap<0.01
Net Debt to EBITDA2.71
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Ocumension Therapeutics has paid 1.02M in taxes.
Income Tax1.02M
Effective Tax Rate>-0.01
Enterprise Valuation
Ocumension Therapeutics EV to EBITDA ratio is -8.47, with an EV/FCF ratio of 0.00.
EV to Sales5.28
EV to EBITDA-8.47
EV to Free Cash Flow0.00
EV to Operating Cash Flow0.00
Balance Sheet
Ocumension Therapeutics has HK$769.21M in cash and marketable securities with ¥25.78M in debt, giving a net cash position of -HK$743.42M billion.
Cash & Marketable SecuritiesHK$769.21M
Total Debt¥25.78M
Net Cash-HK$743.42M
Net Cash Per Share-HK$0.89
Tangible Book Value Per ShareHK$1.94
Margins
Gross margin is 53.93%, with operating margin of -73.43%, and net profit margin of -64.29%.
Gross Margin53.93%
Operating Margin-73.43%
Pretax Margin-64.04%
Net Profit Margin-64.29%
EBITDA Margin-62.32%
EBIT Margin-63.52%
Analyst Forecast
The average price target for Ocumension Therapeutics is HK$6.93, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$6.93
Price Target Upside-23.76% Downside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast66.72%
EPS Growth Forecast33.68%